background image

Paid Clinical Trials Omaha

Discover 658 paid clinical trials in Omaha. Search by condition or phase to find a research study near you that matches your needs across various therapeutic areas.

Filter
2

Efficacy and Safety of Seralutinib in Adult Subjects With PAH (PROSERA)

Recruiting
PHASE3

Sponsor:

GB002, Inc.

Location:

Omaha, Kansas City, Iowa City, Columbiashow 47 more

Code:

NCT05934526

Conditions

Pulmonary Arterial Hypertension

Eligibility Criteria

Sex: All

Age: 18 - 70+

Healthy Volunteers: Not accepted

Interventions

Placebo

Seralutinib

Generic Dry Powder Inhaler

The Patient and Family Centered I-PASS LISTEN Study: Language, Inclusion, Safety, and Teamwork for Equity Now

Recruiting

Sponsor:

Boston Children's Hospital

Location:

Omaha, Amarillo, Columbus, Birminghamshow 4 more

Code:

NCT05591066

Conditions

Communication

Eligibility Criteria

Sex: All

Age: 0 - 70+

Healthy Volunteers: Not accepted

Interventions

PFC I-PASS Intervention

PFC I-PASS+ Intervention

Study to Determine if BHV-7000 is Effective and Safe in Adults With Refractory Focal Onset Epilepsy

Recruiting
PHASE2
PHASE3

Sponsor:

Biohaven Therapeutics Ltd.

Location:

Lincoln, Aurora, Memphis, Shreveportshow 27 more

Code:

NCT06309966

Conditions

Focal Epilepsy

Eligibility Criteria

Sex: All

Age: 18 - 70+

Healthy Volunteers: Not accepted

Interventions

BHV-7000

Placebo

A Longitudinal Observational Study of Patients Undergoing Therapy for IMISC

Recruiting

Sponsor:

Target PharmaSolutions, Inc.

Location:

Omaha, Lincoln, Kansas City, Rochestershow 51 more

Code:

NCT03661866

Conditions

Atopic Dermatitis

Alopecia Areata

Hidradenitis Suppurativa

Vitiligo

Psoriasis

Eligibility Criteria

Sex: All

Age: 0 - 70+

Healthy Volunteers: Not accepted

A Study Evaluating the Efficacy of Budesonide, Glycopyrronium and Formoterol Fumarate Metered Dosed Inhaler on Cardiopulmonary Outcomes in Chronic Obstructive Pulmonary Disease

Recruiting
PHASE3

Sponsor:

AstraZeneca

Location:

Omaha, Fremont, Lincoln, North Sioux Cityshow 195 more

Code:

NCT06283966

Conditions

COPD (Chronic Obstructive Pulmonary Disease)

Eligibility Criteria

Sex: All

Age: 40 - 70+

Healthy Volunteers: Not accepted

Interventions

BGF MDI 320/14.4/9.6 μg

GFF MDI 14.4/9.6 μg

A Study to Investigate the Effect on Lung Function of BDA Formulated With a New Propellant (HFO) Compared With an Approved Asthma Treatment (BDA With HFA Propellant) in Participants With Asthma

Recruiting
PHASE3

Sponsor:

AstraZeneca

Location:

Omaha, Sioux City, Columbia, Saint Louisshow 64 more

Code:

NCT06502366

Conditions

Asthma

Eligibility Criteria

Sex: All

Age: 18+

Healthy Volunteers: Not accepted

Interventions

BDA MDI HFO 160/180 μg

BDA MDI HFA 160/180 μg

Placebo MDI HFA

Harmony TPV Post-Approval Study

Recruiting

Sponsor:

Medtronic Cardiovascular

Location:

Omaha, Saint Louis, Oak Lawn, Aurorashow 16 more

Code:

NCT05077774

Conditions

Congenital Heart Disease

Tetrology of Fallot

RVOT Anomaly

Pulmonary Regurgitation

Eligibility Criteria

Sex: All

Age: 0 - 70+

Healthy Volunteers: Not accepted

Interventions

Harmony TPV System

Evaluating the Addition of Adjuvant Chemotherapy to Ovarian Function Suppression Plus Endocrine Therapy in Premenopausal Patients With pN0-1, ER-Positive/HER2-Negative Breast Cancer and an Oncotype Recurrence Score Less Than or Equal to 25

Recruiting
PHASE3

Sponsor:

NRG Oncology

Location:

Omaha, Council Bluffs, Bellevue, Papillionshow 638 more

Code:

NCT05879926

Conditions

Breast Cancer

Eligibility Criteria

Sex: Female

Age: 18 - 60

Healthy Volunteers: Not accepted

Interventions

Ovarian Function Suppression + Aromatase Inhibitor

Adjuvant Chemotherapy + Ovarian Function Suppression

Study of the Research Medicine CIN-103 in Adults With Irritable Bowel Syndrome With Predominant Diarrhea (IBS-D).

Recruiting
PHASE2

Sponsor:

CinPhloro Pharma, LLC

Location:

Omaha, Weldon Spring, Tulsa, Oak Lawnshow 43 more

Code:

NCT06153420

Conditions

Irritable Bowel Syndrome With Diarrhea

Eligibility Criteria

Sex: All

Age: 18+

Healthy Volunteers: Not accepted

Interventions

CIN-103

Placebo

A Study Evaluating the Efficacy, Safety, Pharmacokinetics and Pharmacodynamics of Crovalimab in Pediatric Participants With Atypical Hemolytic Uremic Syndrome (aHUS)

Recruiting
PHASE3

Sponsor:

Hoffmann-La Roche

Location:

Omaha, Aurora, Cincinnati, Atlantashow 7 more

Code:

NCT04958265

Conditions

Atypical Hemolytic Uremic Syndrome

Eligibility Criteria

Sex: All

Age: 28 - 17

Healthy Volunteers: Not accepted

Interventions

Crovalimab